Search clinical trials for: E2006

Total 95 results

Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

Elderly | Chronic Insomnia | Adults

United States
Eisai Inc.

Completed

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

Metabolism and Excretion

United States
Eisai Inc.

Completed

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

Insomnia

United States
Eisai Inc.

Completed

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Insomnia

United States
Eisai Inc.

Completed

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

CNS

United States
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Eisai Inc.

Completed

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Parkinson's Disease

United States
Eisai Inc.

Terminated

A Study of E2007 In Patients With Parkinson's Disease

Parkinson's Disease

United States
Eisai Inc.

Completed

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Migraine Prophylaxis

United States
Eisai Inc.

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

Narcolepsy Type 1 (NT1)
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Neuralgia

United States, Canada
Eisai Co., Ltd.

Completed

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Epilepsy

Germany
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Terminated

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease
Eisai Inc.

Completed

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Epilepsy

United States, Latvia
Eisai Korea Inc.

Completed

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Korea, Republic of
Eisai Co., Ltd.

Completed

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Healthy Participants

Japan
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Healthy Subjects

China
Eisai Co., Ltd.
Eisai Limited

Completed

Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

Epilepsy

Latvia
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Epilepsy | Partial Onset Seizures

India
Eisai Limited

Completed

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Partial Seizures
Eisai Co., Ltd.

Completed

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Epilepsy

Japan
Eisai Korea Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Epilepsy

Korea, Republic of
Eisai GmbH

Completed

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Seizures

Germany
Eisai Inc.

Available

An Extended Access Program (EAP) for Perampanel

Lennox Gastaut Syndrome | Primary Generalized Tonic-Clonic or Partial Onset Seizures

Belgium, Chile, Estonia, Hungary, Latvia, Lithuania, Poland, Spain
Eisai Inc.

Completed

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Hong Kong, Italy, Australia, Spain, Portugal, Taiwan, India, Thailand, Hungary, Poland, Bulgaria, Serbia, Russian Federation, Korea, Republic of, Ukraine, Romania, Latvia, Lithuania, Germany, Estonia, Czech Republic, Philippines, Ma...
Eisai Inc.

Completed

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Epilepsy

United States
Eisai Limited

Completed

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

Parkinson's Disease

Czech Republic, France, Germany, Italy, Serbia, Spain
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, Chile, Brazil, Canada, Mexico, Argentina
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
Eisai Limited

Completed

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Poland, France, Spain, Germany, Hungary, Italy, Estonia, South Africa, Belgium, United Kingdom, Portugal, Austria, Czech Republic, Israel, Lithuania, Serbia, Sweden
Eisai Co., Ltd.

Completed

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Inc.

No longer available

An Extended Access Program for Perampanel

Partial Onset Seizures

Italy, Spain, Belgium, Israel, Poland, Taiwan, Czechia, Finland, Thailand, Malaysia, Argentina, Chile, Canada, Hungary, Australia, Lithuania, Latvia, Estonia, Netherlands, Greece, Hong Kong
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Eisai Co., Ltd.

Completed

A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

Epilepsy | Seizures

Japan
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PROTECT2)

Breast Cancer | Chemotherapy-induced Neutropenia

Spain, United States, Argentina, Chile, India, Malaysia, Puerto Rico, Russian Federation
Eisai Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy

Epilepsy | Partial-onset Seizures
Eisai Inc.

Terminated

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Germany
Eisai Co., Ltd.

Completed

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Inc.

Withdrawn

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Parkinson's Disease

Germany, Italy
GlaxoSmithKline

Completed

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

Influenza

Germany
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)

Breast Neoplasms | Chemotherapeutic Toxicity | Chemotherapy-induced Neutropenia | Neutropenic Complications

Russian Federation, Brazil, India, Mexico, Romania, Ukraine

3

Subscribe